PE20221498A1 - Intermedio util para la sintesis de un inhibidor de sglt y metodo para preparar un inhibidor de sglt utilizando el mismo - Google Patents

Intermedio util para la sintesis de un inhibidor de sglt y metodo para preparar un inhibidor de sglt utilizando el mismo

Info

Publication number
PE20221498A1
PE20221498A1 PE2022001824A PE2022001824A PE20221498A1 PE 20221498 A1 PE20221498 A1 PE 20221498A1 PE 2022001824 A PE2022001824 A PE 2022001824A PE 2022001824 A PE2022001824 A PE 2022001824A PE 20221498 A1 PE20221498 A1 PE 20221498A1
Authority
PE
Peru
Prior art keywords
sglt inhibitor
synthesis
preparing
same
intermediate useful
Prior art date
Application number
PE2022001824A
Other languages
English (en)
Inventor
Youn Jung Yoon
Hee Kyoon Yoon
Original Assignee
Daewoong Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daewoong Pharmaceutical Co Ltd filed Critical Daewoong Pharmaceutical Co Ltd
Publication of PE20221498A1 publication Critical patent/PE20221498A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D407/00Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/04Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/82Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00Processes for the preparation of sugar derivatives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00Processes for the preparation of sugar derivatives
    • C07H1/02Phosphorylation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04Heterocyclic radicals containing only oxygen as ring hetero atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H7/00Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond
    • C07H7/06Heterocyclic radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

SE REFIERE A UN COMPUESTO DE FORMULA QUIMICA 5 DERIVADO DE [(2R,3S,4R,5R)-1-(2,3-DIHIDROBENZOFURAN-4-IL)-2,3,4,5, 6-PENTAHIDROXIHEXAN-1-ONA)] EL CUAL ES UN COMPUESTO INTERMEDIARIO PARA LA SINTESIS DE UN INHIBIDOR DE SGLT.
PE2022001824A 2020-02-27 2021-02-26 Intermedio util para la sintesis de un inhibidor de sglt y metodo para preparar un inhibidor de sglt utilizando el mismo PE20221498A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20200024525 2020-02-27
PCT/KR2021/002507 WO2021172955A1 (ko) 2020-02-27 2021-02-26 Sglt 저해제의 합성에 유용한 중간체 및 이를 이용한 sglt 저해제의 제조 방법

Publications (1)

Publication Number Publication Date
PE20221498A1 true PE20221498A1 (es) 2022-09-29

Family

ID=77490302

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2022001824A PE20221498A1 (es) 2020-02-27 2021-02-26 Intermedio util para la sintesis de un inhibidor de sglt y metodo para preparar un inhibidor de sglt utilizando el mismo

Country Status (14)

Country Link
US (1) US20230096670A1 (es)
EP (1) EP4112612A4 (es)
JP (1) JP7442663B2 (es)
KR (1) KR102572714B1 (es)
CN (1) CN115087649B (es)
AU (1) AU2021225706B2 (es)
BR (1) BR112022014762A2 (es)
CA (1) CA3169604A1 (es)
CL (1) CL2022002326A1 (es)
CO (1) CO2022011686A2 (es)
EC (1) ECSP22067279A (es)
MX (1) MX2022010220A (es)
PE (1) PE20221498A1 (es)
WO (1) WO2021172955A1 (es)

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530124A (en) * 1994-06-30 1996-06-25 The Dupont Merck Pharmaceutical Company Method for preparing cyclic ureas and their use for the synthesis of HIV protease inhibitors
ES2599330T3 (es) * 2008-08-22 2017-02-01 Theracos Sub, Llc Proceso para la preparación de inhibidores de SGLT2
KR101513234B1 (ko) * 2010-09-10 2015-04-17 주식회사 녹십자 Sglt2 억제제로서의 신규 티오펜 유도체 및 이를 포함하는 약학 조성물
US9034921B2 (en) * 2011-06-01 2015-05-19 Green Cross Corporation Diphenylmethane derivatives as SGLT2 inhibitors
US9340521B2 (en) * 2013-03-18 2016-05-17 Green Cross Corporation Method for dual inhibition of SGLT1 and SGLT2 using diphenylmethane derivatives
US10174010B2 (en) * 2014-03-19 2019-01-08 Hangzhou Pushai Pharmaceutical Technology Co., Ltd. Canagliflozin monohydrate and its crystalline forms, preparation methods and uses thereof
WO2016098016A1 (en) 2014-12-17 2016-06-23 Dr. Reddy’S Laboratories Limited Process for the preparation of sglt2 inhibitors
EP3473621B1 (en) 2016-06-17 2021-08-04 Daewoong Pharmaceutical Co., Ltd. Method for producing diphenylmethane derivative
CN108530408A (zh) * 2018-04-13 2018-09-14 海门慧聚药业有限公司 制备达格列净的方法
EP3838894B1 (en) * 2018-08-13 2024-03-13 Daewoong Pharmaceutical Co., Ltd. Method for producing intermediate useful for synethesis of sglt inhibitor

Also Published As

Publication number Publication date
US20230096670A1 (en) 2023-03-30
AU2021225706A1 (en) 2022-09-01
AU2021225706B2 (en) 2024-06-13
JP2023514754A (ja) 2023-04-07
MX2022010220A (es) 2022-10-10
BR112022014762A2 (pt) 2022-10-11
CN115087649B (zh) 2024-07-05
CO2022011686A2 (es) 2022-08-30
CL2022002326A1 (es) 2023-02-10
EP4112612A4 (en) 2024-04-03
ECSP22067279A (es) 2022-09-30
JP7442663B2 (ja) 2024-03-04
KR102572714B1 (ko) 2023-08-31
CA3169604A1 (en) 2021-09-02
KR20210109476A (ko) 2021-09-06
CN115087649A (zh) 2022-09-20
WO2021172955A1 (ko) 2021-09-02
EP4112612A1 (en) 2023-01-04

Similar Documents

Publication Publication Date Title
CY1114213T1 (el) Μεθοδοι απομονωσης κρυσταλλικης μορφης ι της 5-αζακυτιδινης
BRPI0516911A (pt) método para a preparação de um composto e composto de anilina
EA201070994A1 (ru) Конденсированное гетероциклическое производное и его применение
RU2006134276A (ru) Способ получения монатина
UA107175C2 (uk) Спосіб і сполука, призначені для одержання інгібіторів контранспортера натрій-глюкози 2 типу, варіанти
Yoshimitsu et al. Synthesis of pachastrissamine (jaspine B) and its derivatives by the late-stage introduction of the C-2 alkyl side-chains using olefin cross metathesis
MA31163B1 (fr) Dérivé de pyridyl-triazolopyrimidine ou son sel, pesticide la contenant et son procédé de production
BRPI0816554B8 (pt) compostos como antagonistas de receptores de adenosina a1
NO20080080L (no) Organiske forbindelser
PE20221498A1 (es) Intermedio util para la sintesis de un inhibidor de sglt y metodo para preparar un inhibidor de sglt utilizando el mismo
MY197742A (en) Morphinan derivative
Alcaide et al. Stereoselective cyanation of 4-formyl and 4-imino-β-lactams: application to the synthesis of polyfunctionalized γ-lactams
ES2166977T3 (es) Nuevo procedimiento para preparar compuestos intermedios de plaguicidas.
Franck et al. Regioselective synthesis of azetidines or pyrrolidines by selenium-induced cyclization of secondary homoallylic amines
BRPI0516192A (pt) composto, e, método para a preparação de um composto
FR3037953B1 (fr) Procede de synthese de molecules portant une fonction oxyde de nitrile
PE20070603A1 (es) COMPOSICION FARMACEUTICA QUE COMPRENDE UN INHIBIDOR DE ESCUALENO SINTASA Y UN INHIBIDOR DE 3-HIDROXI-3-METILGLUTARIL-CoA-REDUCTASA (HMG-CoA)
BR112023017834A2 (pt) Inibidores de lrrk2 cinase macrocíclicos
MX2023002429A (es) Derivado de biarilo novedoso util como inhibidor de diacilglicerol aciltransferasa 2 y uso del mismo.
Mollet et al. Synthesis of 2-aryl-3-(2-cyanoethyl) aziridines and their chemical and enzymatic hydrolysis towards γ-lactams and γ-lactones
Garcı́a et al. Enantiocontrolled synthesis of C-19 tetrahydrofurans isolated from the marine alga Notheia anomala
Sarabia et al. Exploring the reactivity of chiral glycidic amides for their applications in synthesis of bioactive compounds
WO2022059013A8 (en) Crystalline form of aspacytarabine
Tamura et al. Stereoselective vinylogous Mannich reaction of 2-trimethylsilyloxyfuran with N-gulosyl nitrones
ZA202207850B (en) Methods, processes and intermediates for preparing chroman compounds